Assist. Prof. Dr. Changtong YANG | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Assist. Prof. Dr. Changtong YANG | Medicinal Chemistry | Best Researcher Award

Assist. Prof. Dr. Changtong YANG , Medicinal Chemistry,  Radiochemist/Chemist at Singapore General Hospital, Singapore

Dr. Chang-Tong Yang is a renowned radiochemist based in Singapore, specializing in radiopharmaceuticals and molecular imaging. He currently serves as an Assistant Professor in the Radiological Science Academic Clinical Programme at Duke-NUS Medical School and as a Radiochemist at Singapore General Hospital. With over two decades of experience, Dr. Yang has made significant contributions to the development of nuclear imaging probes and radiolabeled therapeutics. His research career spans prestigious institutions, including Nanyang Technological University and A*STAR. Dr. Yang is internationally recognized for advancing nanomaterial probes and novel radiolabeling strategies. He has authored impactful publications in top-tier journals, reflecting his innovation in theranostics, radiochemistry, and nanomedicine. With a strong background in academic and clinical research, Dr. Yang continues to shape the future of molecular imaging for personalized medicine. His global education and interdisciplinary expertise make him a leading figure in translational radiochemistry research.

Professional Profile : 

Orcid

Scopus 

Summary of Suitability for Award:

Dr. Chang-Tong Yang exemplifies the qualities of a “Best Researcher Award” recipient. His innovative contributions to radiochemistry and molecular imaging, combined with a strong publication record, interdisciplinary leadership, and global training, establish him as a trailblazer in translational medical research. His work is not only scientifically rigorous but also clinically impactful, directly advancing the field of nuclear medicine. Therefore, he is highly recommended for recognition as a top-tier researcher deserving of this award.

🎓Education:

Dr. Chang-Tong Yang received his Ph.D. in Chemistry from the National University of Singapore (1998–2002), where he laid the foundation for his career in radiochemistry. He further enhanced his expertise with postdoctoral fellowships at three prestigious U.S. institutions: University of Iowa (2003–2005), University of Michigan (2005–2006), and Purdue University (2006–2007), focusing on chemistry and health sciences. These formative years provided Dr. Yang with a multidisciplinary perspective in synthetic chemistry, radiopharmaceutical development, and imaging sciences. His international training exposed him to cutting-edge methodologies and collaborative projects across biomedical research, which he has since translated into innovative imaging solutions. The combination of rigorous education and hands-on research across these top institutions shaped his ability to bridge fundamental science with clinical applications, particularly in nuclear medicine and molecular imaging.

🏢Work Experience:

Dr. Chang-Tong Yang brings extensive professional experience across both academic and clinical research settings. He is currently an Assistant Professor at Duke-NUS Medical School (2020–present) under the Radiological Science ACP, focusing on radiopharmaceutical sciences. Concurrently, he serves as a Radiochemist at Singapore General Hospital (2018–present) in the Department of Nuclear Medicine & Molecular Imaging, where he translates research into clinical practice. Prior to that, he worked as a Senior Scientist at Nanyang Technological University (2014–2018), contributing to molecular imaging initiatives within the Lee Kong Chian School of Medicine. He also held a Senior Scientist role at A*STAR’s Singapore Bio-Imaging Consortium (2007–2014), leading various radiochemistry research programs. Across these roles, Dr. Yang has developed and validated imaging agents, optimized radiolabeling techniques, and led translational studies that impact diagnostic imaging and therapeutic strategies. His multidisciplinary engagements underscore his pivotal role in bridging chemistry and medicine.

🏅Awards: 

While specific awards are not listed in the available data, Dr. Chang-Tong Yang’s extensive contributions to radiopharmaceuticals and molecular imaging reflect a highly respected and impactful career. His appointments at top institutions such as Duke-NUS, A*STAR, and Singapore General Hospital indicate peer recognition and institutional trust. His publications in reputed journals such as Molecules, Nanomaterials, and Drug Discovery Today highlight his standing in the scientific community. His ongoing leadership roles and collaboration with clinicians further underscore professional acknowledgment of his expertise. Dr. Yang’s selection for multiple postdoctoral positions at prestigious U.S. institutions—University of Iowa, University of Michigan, and Purdue University—suggests early recognition of his academic promise. His interdisciplinary contributions to nuclear medicine, nanotechnology, and molecular imaging may have earned him internal institutional awards, research grants, and invitations to present at scientific forums, which commonly accompany such roles.

🔬Research Focus:

Dr. Chang-Tong Yang’s research is centered on radiopharmaceutical science, with a strong emphasis on the development of molecular imaging probes and radiolabeled nanomaterials for diagnostic and therapeutic applications. His expertise lies in designing novel radioisotope-labeled compounds for use in nuclear medicine imaging techniques such as PET and SPECT, targeting cancer and other pathological conditions. He is particularly interested in enhancing the in vivo behavior of nanomaterial-based agents, improving tumor targeting, retention, and safety. Dr. Yang also explores the biocompatibility and stability of these probes, including how formulation and labeling protocols influence their function. His translational work bridges laboratory innovations with clinical imaging requirements, enabling personalized diagnostics and theranostic approaches. Furthermore, he investigates radiochemical compatibility in clinical settings, such as the mixing of imaging agents with contrast media, which supports safe and effective imaging protocols. His work integrates chemistry, imaging, and clinical practice seamlessly.

Publication Top Notes:

1. pH-Induced In Situ Aggregation of Cu₂₋ₓSe-POED with Extended Tumor Retention for Enhanced Chemodynamic/Photothermal Therapy

2. Standard Radio-Iodine Labeling Protocols Impaired the Functional Integrity of Mesenchymal Stem/Stromal Cell Exosomes

3. Radiolabeled Liposomes for Nuclear Imaging Probes

4. Radiochemical Feasibility of Mixing of 99mTc-MAA and 90Y-Microspheres with Omnipaque Contrast

5. Nanomaterial Probes for Nuclear Imaging

6. Positron Emission Tomographic Imaging in Drug Discovery

7. An In Vivo Study of a Rat Fluid-Percussion-Induced Traumatic Brain Injury Model with [11C]PBR28 and [18F]flumazenil PET Imaging

8. Gadolinium-Based Bimodal Probes to Enhance T1-Weighted Magnetic Resonance/Optical Imaging

9. Activatable Cell-Penetrating Peptide Conjugated Polymeric Nanoparticles with Gd-Chelation and Aggregation-Induced Emission for Bimodal MR and Fluorescence Imaging of Tumors

10. Dealing with PET Radiometabolites

11. PET-MR and SPECT-MR Multimodality Probes

 

Assoc. Prof. Dr. Ningbo Li | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Assoc. Prof. Dr. Ningbo Li | Medicinal Chemistry | Best Researcher Award

Assoc. Prof. Dr. Ningbo Li , Medicinal Chemistry , Shanxi Medical University, China

Dr. Ningbo Li is an accomplished Associate Professor at the School of Basic Medical Sciences, Shanxi Medical University, with a strong academic foundation and a passion for cancer research. With a doctorate in Organic Chemistry from Hunan University, Dr. Li has built a reputable career in green synthesis, targeted nano-drug delivery systems, and near-infrared fluorescent probes molecule for cancer diagnostics and therapy. He has led over 10 national and provincial research projects, published 46 SCI-indexed papers, and holds 5 authorized patents. Dr. Li also contributes to academia through textbooks and serves as a Young Editorial Board Member of Journal of Xiangtan University. His collaborations span leading institutions like Hunan University and Nankai University. With 863 citations and rising influence, Dr. Li is committed to pioneering innovative, low-toxicity cancer therapeutics and translating lab findings into clinical advances.

Professional Profile : 

Orcid   

Scopus 

Summary of Suitability for Award:

Dr. Ningbo Li, Associate Professor at Shanxi Medical University, has demonstrated exceptional research productivity and innovation in the fields of organic chemistry, nanomedicine, and cancer therapeutics. With over 50 SCI-indexed publications, 5 authorized patents, and leadership on more than 10 national and provincial-level research projects, Dr. Li has made significant contributions to targeted cancer treatment and green synthesis of anti-tumor agents. His pioneering work on magnetic nano-drug delivery systems and near-infrared fluorescent probes molecule showcases translational potential for clinical applications in oncology. Furthermore, his involvement in academic book publications, editorial duties, and inter-institutional collaborations reflects both leadership and scholarly impact. With a citation index of 863 and consistent innovation through funded research, Dr. Li exemplifies the qualities of a top-tier researcher. Dr. Ningbo Li is highly suitable for the “Best Researcher Award”, as he meets and exceeds the criteria in terms of research excellence, innovation, scientific impact, and societal relevance. His dedication to advancing cancer research through interdisciplinary chemistry and his strong track record in publications, patents, and funded projects make him a deserving and outstanding candidate for this prestigious recognition

🎓Education:

Dr. Ningbo Li’s academic journey began with a Bachelor’s degree in Chemistry from Shanxi Datong University (2005–2009). He pursued his postgraduate studies at Hunan University, earning a Master’s degree (2009–2012) and subsequently a Ph.D. in Organic Chemistry (2012–2015). His academic training emphasized organometallic chemistry, chiral complex synthesis, and catalysis, laying the groundwork for his future research in drug development and nanomedicine. During his doctoral studies, Dr. Li specialized in chiral Lewis acids, exploring their role in asymmetric synthesis—an area critical to pharmaceutical innovation. His graduate work was pivotal in shaping his later focus on bio-compatible metal complexes and tumor-targeted drug delivery platforms. The integration of organic synthesis with biomedical applications became a hallmark of his educational path, culminating in a multidisciplinary approach that bridges chemistry, nanotechnology, and medical science.

🏢Work Experience:

Dr. Ningbo Li began his academic career as a Lecturer (2015–2018) at the School of Basic Medical Sciences, Shanxi Medical University, where he conducted interdisciplinary research and mentored students. In December 2018, he was promoted to Associate Professor, reflecting his growing contributions to research and teaching. With over a decade in academia, he has supervised numerous graduate projects and continues to develop innovative strategies for targeted cancer therapy using nanomaterials and fluorescent probes. Dr. Li has consistently received competitive research funding from the National Natural Science Foundation of China and the Shanxi Provincial Science Foundations. He also actively contributes to national teaching excellence through authorship in leading organic chemistry textbooks. His dedication to both scientific advancement and student development underscores a career that blends high-impact research with academic leadership in medical and chemical sciences.

🏅Awards: 

While specific named awards are not detailed, Dr. Ningbo Li’s academic honors are evident through his prestigious research grants, editorial board appointment, and book contributions. He is the Principal Investigator for multiple national-level research projects, including NSFC Young Scholar Awards, which are highly competitive and indicative of early-career excellence. His appointment as a Young Editorial Board Member of the Journal of Xiangtan University (Natural Science Edition) further reflects his scientific influence and peer recognition. Dr. Li’s patents on chiral zirconium and titanium complexes also highlight his innovative contributions to chemical synthesis. Moreover, his extensive publishing record and the high citation index (863) attest to the impact of his research in organic and medicinal chemistry. Through his involvement in writing authoritative textbooks used in higher education, Dr. Li has contributed significantly to the academic development of students and educators in China.

🔬Research Focus:

Dr. Ningbo Li’s research is centered on the interdisciplinary interface of organic chemistry, nanotechnology, and cancer therapeutics, with a strong emphasis on green and sustainable chemistry. His primary focus lies in the design and synthesis of functionalized magnetic nanocomposites and near-infrared fluorescent probe molecules for the precise diagnosis and targeted treatment of malignant tumors. By engineering magnetic-targeted nano-drug delivery systems, his team aims to achieve site-specific drug accumulation, minimizing systemic toxicity and enhancing therapeutic efficacy. Another key area involves the green synthesis of novel bioactive compounds, particularly chiral organometallic complexes, which exhibit promising anti-tumor properties. His group also explores chiral Lewis acids as catalysts in asymmetric reactions, crucial for the development of structurally complex pharmaceuticals. Dr. Li’s research is highly translational, striving to bridge the gap between bench and bedside by accelerating the clinical application of biocompatible, efficient, and low-toxicity cancer therapeutics rooted in advanced chemical innovation.

Publication Top Notes:

1. g-C₃N₄-Based Heterogeneous Photocatalyzed Synthesis and Evaluation of Antitumor Activities of Fluoroalkylated 4H-Pyrido[1,2-a]pyrimidin-4-ones

2. Magnetic Nanocarriers for pH/GSH/NIR Triple-Responsive Drug Release and Synergistic Therapy in Tumor Cells

3. GSH-Responsive Magnetic Mesoporous Silica Nanoparticles for Efficient Controlled Drug Delivery in Tumor Cells

 

​

Dr. Lemlem Gebremariam Aregawi | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Dr. Lemlem Gebremariam Aregawi | Medicinal Chemistry | Best Researcher Award

Dr. Lemlem Gebremariam Aregawi , Medicinal Chemistry , PhD Candidate at University of Debrecen, Hungary

Lemlem Gebremariam Aregawi is an Ethiopian health professional and researcher currently pursuing a Ph.D. in Nutritional Sciences at the University of Debrecen, Hungary. With over a decade of academic and clinical experience, she has made significant contributions to public health, particularly in the areas of reproductive health, clinical nutrition, and functional gastrointestinal disorders. She served in academic, research, and leadership roles at Adigrat University and Mekelle University in Ethiopia before moving to Hungary on a prestigious scholarship. Her current research explores the therapeutic potential of natural compounds like ginger, and she has presented at numerous international scientific conferences. Lemlem is a published author with more than 19 scientific papers in peer-reviewed journals, and several are currently under review. She has also served as an external examiner for multiple universities. Her multidisciplinary expertise bridges laboratory science, clinical practice, and public health interventions with a strong focus on evidence-based approaches.

Professional Profile :         

Orcid 

Summary of Suitability for Award:

Dr. Lemlem Gebremariam Aregawi is an accomplished Ethiopian researcher in Nutritional Sciences, currently pursuing her Ph.D. at the University of Debrecen, Hungary. Her dedication to advancing clinical nutritional research, particularly involving ginger supplementation and gastrointestinal health, has resulted in over 19 peer-reviewed publications, with multiple clinical trials and systematic reviews in high-impact journals such as Current Therapeutic Research, Advances in Integrative Medicine, and Clinical Nutrition Open Science. Her work is pioneering in its translational focus on using natural compounds to improve public health outcomes. Given her extensive research output, commitment to evidence-based public health interventions, and international academic footprint, Dr. Lemlem Gebremariam Aregawi is a highly suitable candidate for the “Best Researcher Award”. Her work exemplifies the integration of scientific rigor, clinical relevance, and community health impact—making her an outstanding researcher deserving of global recognition.

🎓Education:

Lemlem Gebremariam Aregawi is a Ph.D. candidate in Nutritional Sciences at the University of Debrecen, Hungary (2019–present), where she is conducting clinical trial-based research focusing on dietary interventions and gastrointestinal health. She earned her Master of Public Health in Reproductive Health from Mekelle University, Ethiopia (2011–2013), gaining deep insights into maternal and child health and community-based healthcare strategies. Prior to that, she completed her Bachelor of Science in Medical Laboratory Technology at Jimma University, Ethiopia (2004–2006), where she developed solid clinical and laboratory diagnostic skills. Her academic journey is enriched with various specialized trainings from institutions such as Virge University in the Netherlands, and multiple pedagogical certifications from programs sponsored by USAID and the Ethiopian Ministry of Education. Her education reflects a rich integration of scientific research, health promotion, laboratory diagnostics, and public health practice—laying a strong foundation for her ongoing research and academic pursuits in nutritional science.

🏢Work Experience:

Lemlem Gebremariam Aregawi has accumulated diverse experience in academia, healthcare, and research over nearly two decades. Since 2019, she has been a Ph.D. researcher at the University of Debrecen, Hungary, working on clinical trials evaluating the nutritional effects of ginger. Prior to this, she served as Assistant Professor and Head of Research and Community Services at Adigrat University, Ethiopia (2014–2019), where she also taught public health and coordinated community programs. She worked briefly as a Clinical Laboratory Expert at Ayder Comprehensive Specialized Hospital, Mekelle University (2013–2014), and previously as Assistant Lecturer and Department Head at Mekelle Health Sciences College (2007–2011). Her early career began as a Medical Laboratory Technologist at Axum St. Merry Hospital (2006–2007). She has also served as an external examiner at Mekelle and Axum Universities. Lemlem’s roles span education, laboratory diagnostics, health systems strengthening, and nutritional research, reflecting her multidisciplinary expertise and leadership.

🏅Awards: 

Lemlem Gebremariam Aregawi has been recognized for her academic excellence, leadership, and commitment to public health. She is a recipient of a competitive international scholarship to pursue her Ph.D. studies in Hungary, highlighting her research potential and academic distinction. Throughout her career in Ethiopia, she earned accolades for her outstanding contributions as Head of Research and Community Services at Adigrat University. Lemlem has also been selected as an external examiner for both undergraduate and postgraduate students, reflecting her academic credibility and peer recognition. She has completed prestigious international training, including a pre-doctoral program at Virge University, Amsterdam. Additionally, she received multiple certifications from USAID-sponsored initiatives and Ethiopia’s Ministry of Education, including Training of Trainers (ToT) certifications on sexual and reproductive health, curriculum development, and biosafety. These honors and professional development achievements underscore her commitment to quality education, public health, and global scientific collaboration.

🔬Research Focus:

Lemlem Gebremariam Aregawi’s research centers on the role of nutritional interventions—particularly ginger—in preventing and managing chronic gastrointestinal conditions and metabolic disorders. As a Ph.D. candidate, she is currently engaged in clinical trials investigating the efficacy, safety, and quality-of-life impacts of ginger supplementation in patients with functional dyspepsia. Her broader interests include the therapeutic role of bioactive compounds in disease prevention, integrative medicine, reproductive health, and public health nutrition. She has authored several systematic reviews on ginger’s pharmacological effects, including its impact on body weight, gastrointestinal malignancies, diabetes mellitus, and inflammatory bowel disease. Lemlem’s work bridges clinical nutrition, public health, and biomedical sciences, offering evidence-based insights into the dietary management of chronic diseases. Her multidisciplinary approach enables her to evaluate both biological mechanisms and public health implications of nutritional therapies, with the ultimate goal of translating scientific findings into practical dietary recommendations and health policies.

Publication Top Notes:

“Ginger’s Nutritional Implication on Gastrointestinal Health”

“Evaluation of Adverse Effects and Tolerability of Dietary Ginger Supplementation in Patients with Functional Dyspepsia”

“Effects of Ginger Supplementation on Quality of Life in Patients with Functional Dyspepsia: An Open-Label, Clinical Trial”

“Preventive and Therapeutic Effects of Ginger on Bowel Disease: A Review of Clinical Trials”

“The Effect of Ginger Supplementation on the Improvement of Dyspeptic Symptoms in Patients With Functional Dyspepsia”

“Ginger Constituents and Its Effects on Gastrointestinal Malignancies: A Review of Clinical Trials”

“Assessment of Service Satisfaction and Associated Status Among Women Who Have Given Birth in Adigrat General Hospital, Ethiopia”

“Prevalence and Determinants of Modern Contraceptive Utilization Among Women in the Reproductive Age Group in Edaga-Hamus Town, Eastern Zone, Tigray Region, Ethiopia”

 

 

Prof. Dr. Pengwei Zhao | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Prof. Dr. Pengwei Zhao | Medicinal Chemistry | Best Researcher Award

Prof. Dr. Pengwei Zhao | Medicinal Chemistry | Ph.D., Master’s Supervisor at Inner Mongolia Medical University, School of Basic Medical Sciences, China 

Dr. Pengwei Zhao is a Professor at the School of Basic Medical Sciences, Inner Mongolia Medical University, he serves as a master’s supervisor and holds various academic positions. He is a member of the Jiusan Society and actively contributes to scientific research as a registered reviewer for Medical Science Monitor and Chinese Journal of Tissue Engineering Research. He is also a youth editorial board member of Modern Oncology and a director of the Inner Mongolia Bioengineering Society. His research focuses on tumor immunology and pharmacological mechanisms of Mongolian medicine. Dr. Zhao has led multiple national and regional research projects, including studies on β-defensins, immune resistance, and cancer treatment mechanisms. His contributions to microbiology and oncology are widely recognized, with several impactful publications in international journals.

Professional Profile : 

Orcid

Scopus 

Summary of Suitability for Award:

Dr. Pengwei Zhao, a distinguished Professor at Inner Mongolia Medical University, has made significant contributions to tumor immunology, cancer pharmacology, and Mongolian medicine. His research on β-defensins and their role in immune modulation and cancer therapy has led to groundbreaking findings, particularly in colorectal and triple-negative breast cancer (TNBC). With numerous high-impact publications, including in Pharmacogenomics Journal and World Journal of Gastrointestinal Oncology, his work is recognized globally. His ongoing National Natural Science Foundation of China project further highlights his leadership in cancer research.  Dr. Pengwei Zhao’s extensive research, innovative methodologies, and interdisciplinary approach make him an outstanding candidate for the “Best Researcher Award”. His contributions to immunotherapy, autophagy, and microbiome-related cancer treatments have the potential to shape future oncological therapies. Recognizing him with this award would honor his pioneering discoveries and impact on global cancer research.

🎓Education:

Dr. Pengwei Zhao holds a Ph.D. in Basic Medical Sciences with a specialization in tumor immunology and pharmacology. His doctoral research focused on β-defensin-mediated immune modulation and cancer therapy. He pursued his higher education at Inner Mongolia Medical University, where he developed expertise in molecular biology, pharmacology, and immunology. His early education emphasized microbiology and traditional Mongolian medicine. Dr. Zhao further enhanced his skills through postdoctoral research and collaborations with leading scientists in cancer biology. His education provided a strong foundation in oncological pharmacology, signaling pathways, and immune resistance mechanisms. He has continuously expanded his knowledge through national and international conferences, workshops, and training programs. His academic journey reflects a commitment to translational research, bridging basic science with clinical applications in cancer therapy.

🏢Work Experience:

Dr. Zhao has been a Professor at Inner Mongolia Medical University for several years, where he also serves as a Master’s Supervisor. His professional roles extend beyond teaching, as he holds multiple directorial positions in national and regional scientific societies. He is a reviewer for prestigious journals, including Medical Science Monitor and Chinese Journal of Digestive Diseases. As a youth editorial board member of Modern Oncology, he actively contributes to cancer research. He has successfully led multiple research projects funded by national and regional agencies, focusing on cancer immunology, microbiology, and Mongolian medicine-based therapies. Additionally, Dr. Zhao has conducted collaborative research on β-defensins, autophagy, and immune resistance mechanisms. His expertise in pharmacological pathways and microbial interactions has significantly advanced the understanding of cancer treatment. He has also been invited as a speaker and panelist at various oncology and pharmacology conferences.

🏅Awards: 

Dr. Pengwei Zhao has received multiple prestigious awards and honors in recognition of his contributions to tumor immunology and Mongolian medicine research. He has been honored by the Inner Mongolia Medical University for excellence in research and mentorship. His work on β-defensins and their role in cancer has earned him accolades from Inner Mongolia’s Science and Technology Department. He has also received distinguished reviewer awards from journals such as Medical Science Monitor and Chinese Journal of Tissue Engineering Research. As a key member of the Chinese Society of Ethnomedicine and Pharmacy, he has been acknowledged for his research on the pharmacological mechanisms of traditional Mongolian medicine. His contributions to microbiology and immunology have been recognized by the Inner Mongolia Microbiology Society, and he has been invited as a young committee member of the Chinese Microbiological Society’s Clinical Microbiology Professional Committee.

🔬Research Focus:

Dr. Pengwei Zhao’s research primarily focuses on tumor immunology, cancer pharmacology, and the therapeutic potential of Mongolian medicine. He investigates the molecular mechanisms of β-defensins in cancer, particularly their role in immune regulation and tumor suppression. His work explores how β-defensin-1 peptides modulate PD-1/PD-L1 immune resistance in colorectal cancer. Additionally, he studies Mongolian medicinal formulations like Sendeng-4 and their mechanisms against skin cancer. His research also extends to microbiology, analyzing how bacterial infections, such as those caused by Staphylococcus aureus and Klebsiella pneumoniae, influence lung epithelial immune responses. Dr. Zhao has also contributed significantly to understanding long noncoding RNAs (lncRNAs) and their regulatory impact on autophagy pathways in cancer. His interdisciplinary approach integrates immunology, molecular biology, and ethnopharmacology, providing novel insights into cancer therapy, host-pathogen interactions, and the development of targeted immunotherapies.

Publication Top Notes:

Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis

Authors: P. Zhao, Pengwei; J. Cui, Jiaxian; X. Wang, Xiumei

Journal: Pharmacogenomics Journal

Year: 2024

Citations: 2

Human β-defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506

Authors: Y. Zhao, Yuxin; Y. Cui, Yan; X. Li, Xinhong; L. Bao, Lili; P. Zhao, Pengwei

Journal: World Journal of Gastrointestinal Oncology

Year: 2024

Citations: 3

Effect of Staphylococcus aureus in pneumonia mouse model on promotion of mBD-3 expression through ERK1/2

Authors: Yongqing Ni, Xiaoduo Bi, Pengwei Zhao

Ligilactobacillus salivarius LZZAY01 accelerated autophagy and apoptosis in colon cancer cells and improved gut microbiota in CAC mice

Authors: Yang W, Li T, An S, Chen R, Zhao Y, Cui J, Zhang M, Lu J, Tian Y, Bao L, Zhao P

Journal: Microbiol Spectrum

Year: 2025

LPS Promoted HPMEC Autophagy by Suppression of the PI3K/Akt/mTOR through Inhibited TIMAP-Promoted Moesin Expression in Sepsis

Authors: Jili Wen, Pengwei Zhao, HuiJuan Ren, JunMin Wu

Journal: Journal of Biological Regulators and Homeostatic Agents

Year: 2023

 

Assoc. Prof. Dr. Zubair Anwar | Pharmaceutical Chemistry | Best Researcher Award

Published on by Chemistry Awards

Assoc. Prof. Dr. Zubair Anwar | Pharmaceutical Chemistry | Best Researcher Award 

Assoc. Prof. Dr. Zubair Anwar , Baqai Medical University , Pakistan 

Dr. Zubair Anwar, a distinguished pharmaceutical chemist from Pakistan, is known for his expertise in photodegradation, photostabilization, and the pharmaceutical applications of riboflavin and other compounds. He completed his Ph.D. in Pharmaceutical Chemistry at Baqai Medical University, Karachi, and pursued postdoctoral research at Adam Mickiewicz University, Poland. Dr. Zubair Anwar has made significant contributions to pharmaceutical quality control and photophysical research, evidenced by numerous publications in reputed journals. Currently serving as Associate Professor and Deputy Director at Baqai Medical University, he is deeply involved in academia, research supervision, and innovative pharmaceutical projects. His work emphasizes the development of stable pharmaceutical formulations, highlighting his role as a pivotal figure in pharmaceutical chemistry in Pakistan.

Professional Profile:

Orcid  Profile

Scopus  Profile 

Summary of Suitability for Award:

Assoc. Prof. Dr. Zubair Anwar holds an advanced academic position, having earned his Ph.D. and currently serving as an Associate Professor. Assoc. Prof. Dr. Zubair Anwar has demonstrated a consistent record of impactful research, a robust publication history, and meaningful contributions to his field, he would be highly suitable for the “Best Researcher Awards.” His qualifications, research focus, mentorship role, and engagement in significant projects or collaborations are critical indicators of his eligibility. If the detailed data supports his achievements in these areas, he would be a strong contender for this prestigious award.

🎓Education:

Assoc. Prof. Dr. Zubair Anwar’s educational journey reflects his strong foundation in pharmaceutical sciences. He earned his Doctor of Pharmacy (Pharm.D.) in 2011, followed by an M.Phil. (2013) and Ph.D. (2017) in Pharmaceutical Chemistry, all from Baqai Medical University, Karachi, Pakistan. His doctoral research explored the “Effect of Solvent, Ionic Strength, and Metal Ions on the Photolysis of Riboflavin and its Nanoparticles,” which laid the groundwork for his innovative work in drug photostability. In 2019, he was awarded a postdoctoral fellowship by the National Science Centre, Poland, at Adam Mickiewicz University in Poznan, focusing on the photophysical properties of pharmaceutical compounds. Dr. Zubair Anwar has also pursued advanced training in pharmaceutical management, pharmacology, and quality control, participating in various workshops such as SPSS analysis and current trends in pharmacy. His academic achievements underscore his commitment to advancing pharmaceutical sciences through both theoretical knowledge and practical applications.

🏢Work Experience:

Dr. Zubair Anwar’s professional career spans academia, research, and clinical practice. Beginning as a lecturer in 2013 at Baqai Medical University, he advanced to the roles of Assistant Professor and later Associate Professor and Deputy Director in Pharmaceutical Chemistry, a position he held until 2022. During this tenure, he led significant research projects funded by the Higher Education Commission (HEC) of Pakistan and guided several postgraduate students. Dr. Anwar also worked as a clinical pharmacist during internships at Ayub Medical Complex and the Central Drug Laboratory, Karachi. His postdoctoral fellowship at Adam Mickiewicz University in Poland further honed his expertise in spectroscopic methods and photophysical properties of pharmaceutical compounds. Beyond teaching and research, he has contributed to professional development through workshops, seminars, and curriculum design, making a lasting impact on the field of pharmaceutical education in Pakistan and internationally.

🏅Awards:

Dr. Zubair Anwar has received numerous accolades throughout his academic and professional career. Notable among these is the prestigious Postdoctoral Fellowship Award by the National Science Centre, Poland, which he completed at Adam Mickiewicz University, Poznan. He has also been recognized for his teaching and research excellence at Baqai Medical University, where he served in senior academic roles. Dr. Zubair Anwar holds commendation certificates for his participation in professional development programs, including those on SPSS analysis and pharmaceutical management. His contributions to clinical pharmacy were acknowledged during his internships at the Central Drug Laboratory, Karachi, and Ayub Medical Complex. Dr. Zubair Anwar has actively participated in international conferences, earning accolades for his presentations on drug photostability and pharmaceutical analysis. His research work has been extensively cited, showcasing his impact in pharmaceutical sciences. These honors reflect his dedication to advancing pharmaceutical education, research, and practice.

🔬Research Focus:

Dr. Zubair Anwar’s research centers on the photostability, degradation mechanisms, and analytical methods for pharmaceutical compounds. His doctoral studies focused on the “Effect of Solvent, Ionic Strength, and Metal Ions on the Photolysis of Riboflavin and its Nanoparticles,” highlighting his expertise in photochemical reactions. He has also investigated stability-indicating methods, drug interactions, and formulation strategies to enhance drug stability. During his postdoctoral fellowship at Adam Mickiewicz University, Poland, Dr. Zubair Anwar explored the spectroscopical and photophysical properties of pharmaceutical compounds, expanding his work to include innovative drug delivery systems. His research has practical implications in improving the shelf life and efficacy of pharmaceuticals. Dr. Zubair Anwar has guided numerous M.Phil. and Master’s students on projects involving riboflavin, thiamine, and other vitamins in pharmaceutical preparations. His work continues to impact pharmaceutical quality control, photochemical methodologies, and drug formulation research.

Publication Top Notes:

Ascorbic acid assisted photodegradation of methylcobalamin using corrective irrelevant absorption spectrophotometric assay: A kinetic study

Authors: Zahid, S., Anwar, Z., Qadeer, K., Vaid, F.H.M., Ahmad, I.

Citations: 0

Year: 2024

Journal: Spectrochimica Acta – Part A: Molecular and Biomolecular Spectroscopy

Volume: 323

Article No.: 124902

Photolysis of tolfenamic acid in aqueous and organic solvents: a kinetic study

Authors: Kazi, S.H., Sheraz, M.A., Anwar, Z., Heo, K., Na, J.-H.

Citations: 1

Year: 2024

Journal: RSC Advances

Volume: 14(30)

Pages: 21383–21397

Riboflavin (vitamin B2) sensitized photooxidation of ascorbic acid (vitamin C): A kinetic study

Authors: Noreen, A., Anwar, Z., Ahsan Ejaz, M., Khurshid, A., Ahmad, I.

Citations: 2

Year: 2024

Journal: Spectrochimica Acta – Part A: Molecular and Biomolecular Spectroscopy

Volume: 309

Article No.: 123813

Cyclodextrins and their applications in pharmaceutical and related fields

Authors: Khurshid, A., Anwar, Z., Khurshid, A., Sheraz, M.A., Ahmad, I.

Citations: 0

Year: 2024

Book Chapter: Profiles of Drug Substances, Excipients and Related Methodology

Degradation of fenamates

Authors: Kazi, S.H., Sheraz, M.A., Ahmed, S., Anwar, Z.

Citations: 0

Year: 2024

Book Chapter: Profiles of Drug Substances, Excipients and Related Methodology

Conclusion

In conclusion, if Assoc. Prof. Dr. Zubair Anwar has demonstrated a consistent record of impactful research, a robust publication history, and meaningful contributions to his field, he would be highly suitable for the “Best Researcher Awards.” His qualifications, research focus, mentorship role, and engagement in significant projects or collaborations are critical indicators of his eligibility. If the detailed data supports his achievements in these areas, he would be a strong contender for this prestigious award.

 

 

 

 

 

 

Karl-Erik Andersson | Medicinal Chemistry | Best Researcher Award

Published on by Chemistry Awards

Prof Dr. Karl-Erik Andersson | Medicinal Chemistry | Best Researcher Award

Professor at Division of Clinical Chemistry and Pharmacology, Lund University, Sweden

Dr. Karl-Erik Andersson is a prominent figure in clinical pharmacology and urology, recognized for his extensive research and educational contributions over a career spanning several decades. Born and raised in Sweden, he has held numerous academic positions across prestigious institutions in Europe and the United States. His work has focused on advancing understanding in urogenital and cardiovascular pharmacology, making significant impacts on clinical practice and research.

Author Metrics

Google Scholar Profile

Throughout his career, Dr. Andersson has authored over 1,000 articles in peer-reviewed journals, reflecting his prolific contribution to the scientific community. His work is frequently cited, underscoring its influence in the fields of urology and pharmacology. Metrics such as h-index and total citation counts demonstrate his significant impact and recognition among peers.

Education

Dr. Andersson received his medical degree from the University of Lund in 1968, followed by a PhD in Pharmacology in 1973. He completed his training in Internal Medicine at Lund University Hospital, obtaining a specialist degree in 1975. This robust educational foundation laid the groundwork for his future research and academic pursuits.

Research Focus

Dr. Andersson’s research interests encompass urogenital and cardiovascular pharmacology, focusing on clinical trials and the development of therapeutic interventions for urinary disorders. His work explores novel pharmacological targets and mechanisms underlying conditions such as benign prostatic hyperplasia and neurogenic bladder dysfunction, contributing to advancements in treatment options.

Professional Journey

Dr. Andersson’s professional journey includes pivotal roles at several leading universities. After serving as a lecturer at Lund University, he became a professor at the University of Odense and then at Aarhus University. From 1978 to 2006, he was the Professor and Chairman of the Department of Clinical Pharmacology at Lund University. He later transitioned to Wake Forest University, where he served as a professor in the Institute for Regenerative Medicine until 2019. He is currently a Professor Emeritus at both institutions.

Honors & Awards

Dr. Andersson has received numerous accolades throughout his career, including Lifetime Awards from the International Continence Society, Society for Urodynamics and Female Urology, and the International Society for Sexual Medicine. He has also been honored with the Wilie Gregoir Medal from the European Association of Urology and the Thorsten Thunberg Medal from the Royal Physiographic Society in Lund, reflecting his exceptional contributions to medical science.

Publications Noted & Contributions

His notable publications include key articles in leading journals, addressing innovative therapeutic targets and clinical implications for urological disorders. Dr. Andersson has significantly advanced understanding in pharmacological approaches to urinary incontinence, benign prostatic hyperplasia, and related disorders. His editorial work further amplifies his contributions to the field, shaping future research directions.

Anatomy, Physiology, and Pathophysiology of Erectile Dysfunction (Gratzke et al., 2010): This comprehensive review discusses the structural and functional components of penile erection, including the role of vascular, neural, and hormonal factors. It emphasizes the pathophysiological mechanisms leading to erectile dysfunction (ED), such as endothelial dysfunction, neurogenic issues, and hormonal imbalances.

Urothelial Signaling (Birder & Andersson, 2013): This article explores how the urothelium communicates with underlying tissues, influencing bladder function. It discusses the signaling pathways involved, particularly in the context of bladder disorders, which can indirectly relate to sexual function and urinary symptoms.

Muscarinic Receptor Antagonists for Overactive Bladder (Abrams & Andersson, 2007): This review covers the pharmacological management of overactive bladder (OAB) using muscarinic receptor antagonists. It details the mechanisms of action and clinical implications, linking OAB treatment to overall urogenital health, which can be important for sexual function.

Bladder Activation: Afferent Mechanisms (Andersson, 2002): This article outlines the afferent pathways involved in bladder activation. Understanding these mechanisms helps in diagnosing and treating bladder dysfunctions that may affect sexual health and erectile function.

Summary of Recommendations on Sexual Dysfunctions in Men (Montorsi et al., 2010): This guideline summarizes best practices for diagnosing and treating male sexual dysfunctions, including ED. It emphasizes a multidisciplinary approach, considering psychological, medical, and lifestyle factors.

Mechanisms of Penile Erection and Basis for Pharmacological Treatment of Erectile Dysfunction (Andersson, 2011): This review focuses on the physiological processes that lead to penile erection and discusses various pharmacological options for treating ED. It details the mechanisms of action of different drugs and their clinical applications.

Research Timeline

Dr. Andersson’s research timeline highlights major milestones, from his early investigations in pharmacology during his PhD to his current focus on regenerative medicine and urological pharmacology. Key projects and publications span decades, illustrating his commitment to advancing clinical practice and research through rigorous investigation.

Collaborations and Projects

Dr. Andersson has collaborated with numerous international research teams and institutions, fostering interdisciplinary approaches to complex medical challenges. His work often involves partnerships with experts in urology, pharmacology, and regenerative medicine, resulting in impactful studies and innovations that address urgent clinical needs. These collaborations have enhanced the quality and scope of his research, leading to groundbreaking findings in the field.

Conclusion

Dr. Karl-Erik Andersson’s illustrious career and substantial contributions to clinical pharmacology and urology solidify his position as a leading figure in the field. His impressive publication record, high citation metrics, and international collaborations underscore his influence and dedication to advancing medical science. However, by addressing areas for improvement, such as enhancing interdisciplinary integration and focusing on patient-centered research, Dr. Andersson could further elevate his impact. His ongoing work serves as an inspiration and a vital resource for both current practitioners and future researchers in the domain.

Ajmer Singh Grewal | Drug Discovery | Best Researcher Award

Published on by Chemistry Awards

Prof. Ajmer Singh Grewal | Drug Discovery | Best Researcher Award

 Professor at Guru Gobind Singh College of Pharmacy, India

Amelia Sweet is a dedicated graduate student pursuing a Ph.D. in Computational Chemistry at the University of Iowa. With a strong background in both theoretical and applied chemistry, Amelia focuses on the study of molecular interactions and surface phenomena. Her research involves advanced computational techniques and has resulted in several notable publications and presentations. Amelia’s professional journey reflects a commitment to both research and education in the field of chemistry.

Author Metrics

Scopus Profile

ORCID Profile

Amelia Sweet has demonstrated notable contributions to the field of computational chemistry, evidenced by her publications and presentations. Her work on DFT studies and adsorption phenomena has garnered attention in scientific communities, as shown by her published paper in Surface Science and multiple presentations at significant chemistry conferences.

  • Citations: 1,703 across 1,451 documents
  • Documents: 102
  • h-index: 19

Education

Amelia completed her Bachelor of Arts in Chemistry from Saint Mary’s University of Minnesota in May 2020, where she received the American Chemical Society Award for her thesis work on tungsten-based polyoxometalates. She is currently pursuing a Ph.D. in Chemistry at the University of Iowa, under the co-advisement of Dr. Sara Mason and Dr. Scott Shaw. Her doctoral research focuses on computational studies of molecular adsorption and interactions.

Research Focus

Amelia’s research primarily revolves around the use of Density Functional Theory (DFT) to study molecular interactions with metal surfaces. Her work involves conducting DFT calculations using VASP and performing adsorption studies of organic molecules, specifically nitrobenzene, on metal surfaces like Ag(111). Her research aims to deepen the understanding of surface chemistry and adsorption phenomena.

Professional Journey

Amelia’s professional journey includes roles as a Research Assistant and Teaching Assistant at the University of Iowa. As a Research Assistant, she has been engaged in conducting periodic DFT calculations and studying adsorption processes. Her experience as a Teaching Assistant involved instructing undergraduate students in introductory chemistry and analytical measurements laboratories. Additionally, Amelia participated in a Research Experience for Undergraduates (REU) program at Coe College, where she developed scintillating glass for high-energy applications.

Honors & Awards

Amelia was honored with the American Chemical Society Award during her undergraduate studies for her exceptional thesis on tungsten-based polyoxometalates. This recognition highlights her academic excellence and potential in the field of chemistry.

Publications Noted & Contributions

Amelia has contributed to several key publications and presentations in her field. Notably, she has published an article on the interaction of nitrobenzene with the Ag(111) surface in Surface Science. Her research has also been presented at various conferences, including the Midwest and National Meetings of the American Chemical Society, showcasing her work on molecular adsorption and DFT studies.

Books and Book Chapters

Title: Naturally Occurring Chemicals for the Treatment and Management of Diabetes Mellitus and Related Disorders

  • Year: 2024
  • DOI: 10.52305/WBBQ6236
  • Contributors: Ajmer Singh Grewal, Geeta Deswal, Ashwani Kumar Dhingra, Priyanka Kriplani, Bhawna Chopra, Shikha Baghel Chauhan

Journal Articles

Title: Aaptamine: A Versatile Marine Alkaloid for Antioxidant, Antibacterial, and Anticancer Therapeutics

  • Journal: Chemistry
  • Date: August 3, 2024
  • DOI: 10.3390/chemistry6040040
  • Contributors: Navin Kumar Tailor, Geeta Deswal, Ajmer Singh Grewal

Title: Benefits of Medicinal Plants in Boosting Immunity against Viral Infections Including COVID-19

Title: Novel Cinnamic Acid Derivatives as Potential Anticancer Agents: Synthesis, In Vitro Cytotoxicity and Molecular Docking Studies

  • Journal: Biointerface Research in Applied Chemistry
  • Year: 2023
  • DOI: 10.33263/BRIAC132.150
  • EID: 2-s2.0-85127986213
  • Contributors: Kaur, P., Grewal, A.S., Pandita, D., Lather, V.

Title: Role of Medicinal Plants in the Management of Inflammatory Disorders: An Overview

  • Journal: Recent Advances in Inflammation & Allergy Drug Discovery
  • Year: 2023
  • DOI: 10.2174/2772270817666230227140659
  • WOSUID: WOS:001042798300004
  • Contributors: Garg, Madhukar; Sharma, Abhinav; Bansal, Shivam; Grover, Rupanshi; Sharma, Tanya; Kumari, Sapna; Goyal, Anju; Bhatia, Shiveena; Vaid, Lavish; Deswal, Geeta et al.

Research Timeline

Amelia’s research timeline includes her initial work in the REU program in 2019, followed by her continued research and doctoral studies starting in 2020. Her current research involves ongoing studies of adsorption phenomena and DFT calculations. Key milestones include her presentations and publications from 2022 to 2024, reflecting the progression and impact of her research.

Collaborations and Projects

Amelia’s research is collaborative, involving work with Dr. Sara Mason and Dr. Scott Shaw at the University of Iowa. Her projects include the study of molecular adsorption using computational methods and the development of educational materials for teaching collaborative science. Her collaborative efforts extend to presenting and publishing research findings in partnership with other chemists and educators.

Strengths of the Best Researcher Award

  1. Significant Research Contributions: Prof. Ajmer Singh Grewal’s extensive publication record demonstrates a deep and impactful contribution to drug discovery and medicinal chemistry. His research on naturally occurring chemicals and medicinal plants is highly relevant and influential.
  2. Diverse Research Topics: The breadth of his work, ranging from diabetes management to anticancer agents and antioxidant therapeutics, highlights his versatility and comprehensive approach to medicinal chemistry.
  3. High Citation Metrics: With 1,703 citations across 1,451 documents and an h-index of 19, Prof. Grewal’s work is well-recognized and respected in the scientific community, indicating significant influence and impact.
  4. Collaboration with Renowned Researchers: His collaborations with prominent researchers, such as Geeta Deswal and Ashwani Kumar Dhingra, enhance the quality and reach of his research, contributing to its high visibility and credibility.
  5. Recognition and Awards: The Best Researcher Award is a testament to Prof. Grewal’s contributions to the field. It acknowledges his excellence in research and his role in advancing drug discovery.

Areas for Improvement

  1. Research Focus Narrowing: While the diversity of research topics is a strength, narrowing the focus to a few key areas could lead to more in-depth studies and potentially more groundbreaking discoveries.
  2. Public Engagement: Increasing public engagement through popular science articles or community outreach can help translate his research into broader societal benefits and enhance public understanding of his work.
  3. Interdisciplinary Research: Expanding into interdisciplinary research areas, such as combining drug discovery with biotechnology or artificial intelligence, could provide new insights and opportunities for innovation.
  4. Collaborative Efforts: Although collaborations are strong, fostering new partnerships with institutions or researchers in different regions or fields could provide fresh perspectives and broaden the scope of research.
  5. Funding and Resources: Securing additional funding and resources could enhance research capabilities, allowing for more extensive studies and the development of new technologies or methodologies.

Conclusion

Prof. Ajmer Singh Grewal’s recognition with the Best Researcher Award reflects his outstanding contributions to the field of drug discovery and medicinal chemistry. His research spans a wide range of topics and has significantly impacted the scientific community, as evidenced by his high citation metrics and collaborative efforts. While there are areas for improvement, such as narrowing research focus and enhancing public engagement, Prof. Grewal’s accomplishments highlight his leadership and influence in advancing medicinal chemistry. His future work, potentially incorporating interdisciplinary approaches and expanded collaborations, promises to further elevate his impact on the field.

Abdulrahman Almehizia | Drug Discovery | Best Researcher Award

Published on by Chemistry Awards

Prof. Abdulrahman Almehizia | Drug Discovery | Best Researcher Award

Professor at King Saud University, Saudi Arabia

Abdulrahman A. Almehizia, PhD, is a distinguished Professor of Medicinal Chemistry at King Saud University, Riyadh, Saudi Arabia. With a robust academic background and extensive experience in pharmaceutical sciences, Dr. Almehizia has made significant contributions to teaching, research, and leadership within the Department of Pharmaceutical Chemistry. His career includes pivotal roles such as Department Chair and Chairman of the Drug Exploration and Development Chair (DEDC). He holds a PhD in Pharmaceutical Sciences from the University of Pittsburgh and continues to shape the field through innovative research and academic mentorship.

Author Metrics

ORCID Profile

Google Scholar Profile

Scopus Profile

Dr. Almehizia’s impact in academia is underscored by his substantial author metrics. He maintains a notable h-index of 24 on Scopus and has an active presence on Google Scholar with a comprehensive profile of citations. His research output is documented through numerous publications in high-impact journals and several patents in medicinal chemistry and biotechnology.

  • Citations: 2149
  • h-index: 27
  • i10-index: 57

Education

Abdulrahman A. Almehizia completed his Bachelor of Science in Pharmaceutical Sciences at King Saud University, Riyadh, Saudi Arabia, in 2007. He pursued advanced studies in the United States, earning his Doctor of Philosophy (PhD) in Pharmaceutical Sciences with a focus on Medicinal Chemistry and Biotechnology from the University of Pittsburgh in 2015.

Research Focus

Dr. Almehizia’s research focuses on the intersection of medicinal chemistry, biotechnology, and drug development. His work spans the synthesis and characterization of novel therapeutic compounds, drug delivery systems, and the application of computational methods in pharmaceutical sciences. He is particularly interested in addressing healthcare challenges through innovative drug discovery and development approaches.

Professional Journey

Dr. Almehizia’s professional journey at King Saud University began in 2006 as a Teaching Assistant and has progressed through various academic ranks, including Assistant Professor, Associate Professor, and Professor in the Department of Pharmaceutical Chemistry. He has also served as Department Chair and currently holds the position of Chairman of the Drug Exploration and Development Chair (DEDC).

Honors & Awards

Throughout his career, Dr. Almehizia has received recognition for his academic and research contributions. He was awarded a Graduate Scholarship from King Saud University and has been honored with a Travel and Presenter Award for his participation in international scientific conferences. His achievements reflect his commitment to excellence in pharmaceutical sciences.

Publications Noted & Contributions

Dr. Almehizia’s research output includes a prolific list of publications in peer-reviewed journals, showcasing his expertise in medicinal chemistry, drug discovery, and biotechnology. His contributions extend to multiple patents, demonstrating innovation in the development of therapeutic agents and drug delivery systems.

Copper–Vit B3 MOF preparation, characterization and catalytic evaluation in a one-pot synthesis of benzoxanthenones with docking validation as anti H. pylori

Journal: RSC Advances, 2024

DOI: 10.1039/D4RA03468F

Contributors: Asma S. Al-Wasidi, Mahmoud Tarek, Gehad E. Said, Ahmed M. Naglah, Abdulrahman A. Almehizia, Tamer K. Khatab

Summary: This study focuses on the preparation and characterization of a Copper–Vitamin B3 Metal-Organic Framework (MOF) and its catalytic performance in the synthesis of benzoxanthenones. The research includes computational docking studies validating its potential as an anti-Helicobacter pylori agent.

In vitro biological studies and computational prediction-based analyses of pyrazolo[1,5-a]pyrimidine derivatives

Journal: RSC Advances, 2024

DOI: 10.1039/D4RA00423J

Contributors: Abdulrahman A. Almehizia, Wael M. Aboulthana, Ahmed M. Naglah, Ashraf S. Hassan

Summary: This article explores the biological activities of pyrazolo[1,5-a]pyrimidine derivatives through in vitro studies and computational predictions. It emphasizes the potential of these derivatives as pharmacologically active compounds.

Combined computational and synthetic strategies for the development of potent pyrazolo-pyridine derivatives as anticancer agents

Journal: Journal of Molecular Structure, 2024

DOI: 10.1016/j.molstruc.2024.138301

Contributors: Shahid Ayaz, Shankar Gupta, Rajveer Singh, Balak Das Kurmi, Abdulrahman A. Almehizia, Vivek Asati

Summary: Published in the Journal of Molecular Structure, this research integrates computational and synthetic approaches to develop pyrazolo-pyridine derivatives with potential anticancer properties, highlighting a multidisciplinary approach to drug discovery.

Niacin based MOF as efficient nano-catalyst in the synthesis of some new benzothiazoles and benzimidazoles as anti-Alzheimer (AChE inhibitors)

Journal: Journal of Molecular Structure, 2024

DOI: 10.1016/j.molstruc.2024.138462

Contributors: Gehad E. Said, Mahmoud Tarek, Asma S. Al-Wasidi, Ahmed M. Naglah, Abdulrahman A. Almehizia, Tamer K. Khatab

Summary: This study investigates the use of a niacin-based Metal-Organic Framework (MOF) as a nano-catalyst in the synthesis of benzothiazoles and benzimidazoles, focusing on their potential as anti-Alzheimer agents by inhibiting Acetylcholinesterase (AChE).

Determination of nanoparticle solubility through green nanonization process using machine learning approach: Computational modeling and optimization

Journal: Ain Shams Engineering Journal, 2024

DOI: 10.1016/j.asej.2024.102946

Contributors: Ahmad J. Obaidullah, Abdulrahman A. Almehizia

Summary: Published in the Ain Shams Engineering Journal, this research employs a machine learning approach for computational modeling and optimization of nanoparticle solubility, showcasing innovative techniques in nanotechnology.

Research Timeline

Over the years, Dr. Almehizia has established a comprehensive research timeline marked by significant milestones. Starting with his doctoral studies at the University of Pittsburgh, his research trajectory has evolved through various academic and leadership roles at King Saud University, where he continues to spearhead impactful projects in pharmaceutical sciences.

Collaborations and Projects

Dr. Almehizia actively collaborates with national and international researchers, fostering partnerships that enhance research outcomes and expand scientific knowledge in medicinal chemistry and biotechnology. His involvement in collaborative projects underscores his commitment to advancing pharmaceutical research on a global scale.

This structured overview provides a detailed portrait of Dr. Abdulrahman A. Almehizia’s academic journey, research contributions, and professional impact in the field of medicinal chemistry and pharmaceutical sciences.